Navigation Links
AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
Date:3/5/2008

Company commercializes technology from Cincinnati Children's and Mayo

Clinic to help doctors select right drug at right dose for patients

CINCINNATI, March 5 /PRNewswire/ -- AssureRx, a personalized medicine company, today announced that it has closed a round of funding.

The company was founded in 2006 to license and commercialize pharmacogenetic technology from Cincinnati Children's Hospital Medical Center and Mayo Clinic. The technology utilized in the AssureRx non-invasive, pharmacogenetic test measures, analyzes and interprets the genes of patients with common neuro-psychiatric disorders to predict which drugs are best choices for each specific patient. The test helps to take much of the guesswork out of prescribing medications.

"Personalized medicine is the future of health care," said Mark Byrne, chief executive officer of AssureRx. "Our test uses cutting-edge technology to measure, analyze and inform, helping doctors provide customized care based on science. Our comprehensive genetic test, sophisticated interpretive algorithms, quick turnaround and physician-friendly reports provide physicians a unique guide that will save money, save time and save lives."

Pharmacogenetics helps physicians determine how an individual patient will respond to an individual drug, and at what dose. AssureRx analyzes not just one gene, but several genes to predict how patients will respond to medicines. The patent-pending technology takes many genetic variables into consideration and translates the data into a report for doctors within 48 hours of receiving a sample from a patient.

"Until now, doctors have had to determine the safety and effectiveness of psychotropic drug selection and dosing for an individual patient through trial and error," said David Mrazek, M.D., Chair, Mayo Clinic Department of Psychiatry and Psychology. "This technology allows for a personalized patient report based on known science and the specific genetic makeup of the individual patient. The report outlines metabolic factors and drug response information."

Investors include Queen City Angels (lead), CincyTech USA, the Health Foundation of Greater Cincinnati, Blue Chip Venture Company, Cincinnati Children's Tomorrow Fund and individual investors.

"We liked what we saw in terms of the science, the research partners, the business plan, the executive team and the market potential," said John McIlwraith of Blue Chip Venture Company. "Personalized medicine is clearly an emerging trend in patient care. We're happy to be in at the forefront of this exciting opportunity with AssureRx, and we're confident that the company will become a leader in the field."

About AssureRx

Cincinnati-based AssureRx, LLC, is a personalized medicine company dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from a range of medical conditions. The company was founded in June 2006 to license and commercialize industry-leading personalized medicine technology of Cincinnati Children's Hospital Medical Center and Mayo Clinic. The proprietary technology is based on pharmacogenetics - the study of the genetic factors that influence an individual's response to drug treatments - as well as evidence-based medicine and clinical pharmacology. The result is a trusted guide that helps doctors select the right drug at the right dose right now. AssureRx can be found on the Web at http://www.assurerx.biz.


'/>"/>
SOURCE AssureRx
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, 2016 ... provider of genomic services and solutions with cutting edge ... it has completed a USD $75 Million [515 Million ... Ltd.,s CMB International Capital Management ( Shenzhen ... Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment ...
(Date:11/30/2016)... , Nov. 30, 2016   Merck , ... it has entered into a set of agreements with ... for Merck,s collection of genetic reagents such as CRISPR ... Evotec,s screening expertise offers an accelerated pathway to explore ... starts with the identification of new targets, a process ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D Therapeutics, Inc., a clinical ... treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will be ... T3D-959 in mild to moderate Alzheimer’s patients at CTAD 2016. Preliminary results of ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):